Shujie Xia
YOU?
Author Swipe
View article: Extracellular Matrix Stiffness Enhancement Promotes Docetaxel Resistance in Prostate Cancer via Inhibition of Apoptosis Mediated by Upregulation of PRRX1
Extracellular Matrix Stiffness Enhancement Promotes Docetaxel Resistance in Prostate Cancer via Inhibition of Apoptosis Mediated by Upregulation of PRRX1 Open
Background: Prostate cancer (PCa) poses a significant health burden for men, with docetaxel constituting the primary therapeutic option for patients with metastatic PCa. However, the mechanisms governing docetaxel resistance remain …
View article: Clinical value of spontaneous cavernous activity evaluation in identifying misdiagnosed corporal venous occlusive dysfunction in psychogenic erectile dysfunction
Clinical value of spontaneous cavernous activity evaluation in identifying misdiagnosed corporal venous occlusive dysfunction in psychogenic erectile dysfunction Open
The findings suggested that elevated SCA may contribute to CVOD development in psychogenic ED through impaired CSM relaxation due to sympathetic overactivity. SCA assessment might be a useful diagnostic tool for identifying misdiagnosed CV…
View article: ACOT1 eQTL: a gene involved in lipid metabolism that modulates erectile dysfunction progression via metabolites
ACOT1 eQTL: a gene involved in lipid metabolism that modulates erectile dysfunction progression via metabolites Open
Introduction The causal relationship between expression quantitative trait loci (eQTL) and erectile dysfunction (ED) remains underexplored. This study applied Mendelian randomization (MR) analysis to investigate potential causal links betw…
View article: Beyond size: A comprehensive overview of small-volume benign prostatic hyperplasia
Beyond size: A comprehensive overview of small-volume benign prostatic hyperplasia Open
Benign prostatic hyperplasia (BPH) is one of the most frequently diagnosed benign disorders that cause dysuria in middle-aged and elderly men. Some patients with BPH have relatively small prostates (referred to as small-volume BPH) but sti…
View article: Maternal exposure to dibutyl phthalate (DBP) impairs angiogenesis and AR signalling pathway through suppression of TGFB1I1 in hypospadias offspring
Maternal exposure to dibutyl phthalate (DBP) impairs angiogenesis and AR signalling pathway through suppression of TGFB1I1 in hypospadias offspring Open
Early exposure to dibutyl phthalate (DBP) can cause hypospadias in newborn foetuses. However, the underlying molecular mechanism is not well defined. Aberrant angiogenesis is associated with various dysplasias including urogenital deficits…
View article: Mesenchymal stem cell‐derived extracellular vesicles in treatment against renal fibrosis
Mesenchymal stem cell‐derived extracellular vesicles in treatment against renal fibrosis Open
Background Renal fibrosis (RF) is the main pathological pathway of acute kidney injury and chronic kidney disease. Its main pathological feature is extracellular matrix aggregation in the renal stroma and glomerulus. There is currently no …
View article: A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling
A lncRNA from the FTO locus acts as a suppressor of the m6A writer complex and p53 tumor suppression signaling Open
N6-methyladenosine (m6A) of mRNAs modulated by the METTL3-METTL14-WTAP-RBM15 methyltransferase complex and m6A demethylases such as FTO play important roles in regulating mRNA stability, splicing, and trans…
View article: Consensus on safety management of novel hormonal therapy for advanced prostate cancer
Consensus on safety management of novel hormonal therapy for advanced prostate cancer Open
Prostate cancer (PCa) is one of the most prevalent malignant tumors in men, accompanied by high incidence and mortality rates. Novel hormonal therapy (NHT) has emerged as the primary treatment for advanced PCa, providing noticeable clinica…
View article: Data from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals
Data from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals Open
The tumor microenvironment impacts tumor progression and individual cells, including CD4+ T cells, which have been detected in bladder cancer tissues. The detailed mechanism of how these T cells were recruited to the bladder can…
View article: Supplementary Figures 1 - 4 from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Supplementary Figures 1 - 4 from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals Open
PDF file - 267K, Fig. s1. HMECs induce the PCa cells invasion in vitro. Fig. s2. ECs down-regulated AR signaling in PCa cells. Fig. s3. Cytokines/chemokines level changes in ECs upon PCa cells co-culture. Fig. s4. EMT markers expressions c…
View article: Supplementary Table 1 from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals
Supplementary Table 1 from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals Open
Pearson's correlation analysis of key genes in our pathway according to BLCA data set
View article: Data from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Data from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals Open
Although the potential roles of endothelial cells in the microvascules of prostate cancer during angiogenesis have been documented, their direct impacts on the prostate cancer metastasis remain unclear. We found that the CD31-positive and …
View article: Supplementary Figures 1 - 4 from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Supplementary Figures 1 - 4 from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals Open
PDF file - 267K, Fig. s1. HMECs induce the PCa cells invasion in vitro. Fig. s2. ECs down-regulated AR signaling in PCa cells. Fig. s3. Cytokines/chemokines level changes in ECs upon PCa cells co-culture. Fig. s4. EMT markers expressions c…
View article: Data from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals
Data from Endothelial Cells Enhance Prostate Cancer Metastasis via IL-6→Androgen Receptor→TGF-β→MMP-9 Signals Open
Although the potential roles of endothelial cells in the microvascules of prostate cancer during angiogenesis have been documented, their direct impacts on the prostate cancer metastasis remain unclear. We found that the CD31-positive and …
View article: Data from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals
Data from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals Open
The tumor microenvironment impacts tumor progression and individual cells, including CD4+ T cells, which have been detected in bladder cancer tissues. The detailed mechanism of how these T cells were recruited to the bladder can…
View article: Supplementary Figure 1 from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals
Supplementary Figure 1 from Infiltrating T Cells Promote Bladder Cancer Progression via Increasing IL1→Androgen Receptor→HIF1α→VEGFa Signals Open
Pearson's correlation analysis of IL8, IL1 and HIF1A according to BLCA data set
View article: Supplemental Fig. 2 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Fig. 2 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure 2. PF-03084014 combined with docetaxel suppresses tumor cell proliferation, induces apoptosis and inhibits tumor angiogenesis in mice.
View article: Supplemental Fig. 2 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Fig. 2 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure 2. PF-03084014 combined with docetaxel suppresses tumor cell proliferation, induces apoptosis and inhibits tumor angiogenesis in mice.
View article: Data from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Data from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Purpose: To investigate the efficacy and mechanisms of Notch signaling inhibition as an adjuvant to docetaxel in castration-resistant prostate cancer (CRPC) using a γ-secretase inhibitor (GSI), PF-03084014.Experimental Design:
View article: Supplemental Figure Legends from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Figure Legends from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure Legends
View article: Supplemental Fig. 3 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Fig. 3 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure 3. PF-03084014 inhibits notch pathway in prostate cancer tumor xenografts in vivo.
View article: Supplemental Fig. 1 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Fig. 1 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure 1. Genetic knockdown of Notch-1 inhibits growth and docetaxel chemoresistance of prostate cancer cells similar to PF-03084014.
View article: Supplemental Fig. 1 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Fig. 1 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure 1. Genetic knockdown of Notch-1 inhibits growth and docetaxel chemoresistance of prostate cancer cells similar to PF-03084014.
View article: Supplemental Fig. 3 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Fig. 3 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure 3. PF-03084014 inhibits notch pathway in prostate cancer tumor xenografts in vivo.
View article: Data from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Data from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Purpose: To investigate the efficacy and mechanisms of Notch signaling inhibition as an adjuvant to docetaxel in castration-resistant prostate cancer (CRPC) using a γ-secretase inhibitor (GSI), PF-03084014.Experimental Design:
View article: Table S3 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study
Table S3 from Camrelizumab plus Famitinib in Patients with Advanced or Metastatic Renal Cell Carcinoma: Data from an Open-label, Multicenter Phase II Basket Study Open
Immune-related adverse events
View article: Supplemental Figure Legends from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Supplemental Figure Legends from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer Open
Supplemental Figure Legends
View article: Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia
Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia Open
Benign prostatic hyperplasia (BPH) is a condition that becomes more common with age and manifests itself primarily as the expansion of the prostate and surrounding tissues. However, to date, the etiology of BPH remains unclear. In this res…
View article: Activation of the HNRNPA2B1/<i>miR-93-5p</i>/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner
Activation of the HNRNPA2B1/<i>miR-93-5p</i>/FRMD6 axis facilitates prostate cancer progression in an m6A-dependent manner Open
It is becoming increasingly clear that N6-methyladenosine (m6A) plays a key role in post-transcriptional modification of eukaryotic RNAs in cancer. The regulatory mechanism of m6A modifications in prostate cancer is still not completely el…
View article: Comparative RNA-sequencing analysis of the prostate in a mouse model of benign prostatic hyperplasia with bladder outlet obstruction
Comparative RNA-sequencing analysis of the prostate in a mouse model of benign prostatic hyperplasia with bladder outlet obstruction Open
In aging men, BPH is a chronic disease that leads to progressive lower urinary tract symptoms (LUTS) caused by obstruction of the bladder outlet (BOO). Patients with LUTS (such as frequency and urgency) and complications of BOO (such as hy…